Xilio Therapeutics, Inc.
News
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Globe Newswire WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...\n more…
TD Cowen Remains a Buy on Xilio Therapeutics (XLO)
TipRanks Financial Blog TD Cowen analyst Marc Frahm maintained a Buy rating on Xilio Therapeutics (XLO - Research Report) yesterday. The company's shares closed yesterday ...\n more…
Generex Biotechnology (OTCMKTS:GNBT) & Xilio Therapeutics (NASDAQ:XLO) Head-To-Head Review
Ticker Report Generex Biotechnology (OTCMKTS:GNBT - Get Free Report) and Xilio Therapeutics (NASDAQ:XLO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the...\n more…
XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nXLO stock results show that Xilio Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.\nThe post XLO...\n more…
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
Globe Newswire Initiated enrollment in Phase 2 clinical trial of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...\n more…
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Significant Increase in Short Interest
Ticker Report Xilio Therapeutics, Inc. (NASDAQ:XLO - Get Free Report) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 144,900 shares, a growth of 23.1% from...\n more…